BBIO vs MCD · rev $221.9M vs P/E 23, rev $25.92B
BridgeBio Pharma Inc (BBIO) versus McDonald’s Corporation (MCD) — a side-by-side from cached financials, not a winner call.
BridgeBio Pharma Inc (BBIO) is a biotechnology company listed on US.
McDonald’s Corporation (MCD) is a restaurants company listed on NYSE. It is led by Chris Kempczinski.
Latest reported BBIO revenue for 2024-12-31 was $221.9M. Net income was -$543.3M. Revenue was up 2285.3% from 2023-12-31 to 2024-12-31. BBIO currently screens at market cap $13.24B.
Latest reported MCD revenue for 2024-12-31 was $25.92B. Net income was $8.22B. Revenue was up 1.7% from 2023-12-31 to 2024-12-31. MCD currently screens at market cap $201.66B and trailing P/E 23.4.
BBIO currently screens at market cap $13.24B. MCD currently screens at market cap $201.66B and trailing P/E 23.4.
Not investment advice. Open the BBIO and MCD stock pages for the full models.
Not investment advice.